Serrels et al reported that inhibition of Focal Adhesion Kinase (FAK) can drive T-cell-mediated regression of squamous cell carcinoma (SCC) tumors via modulation of the immuno-suppressive microenvironment (Fig. 3a, b), with FAK inhibitors currently tested in clinical trials in combination with immune checkpoint inhibitors49. The gene discussed is PTK2; the disease is squamous cell carcinoma.